Ceiling vs floor price
The one-line test of any advertised GLP-1 figure: under dose-flat pricing the advertised number is a ceiling (it cannot go up as you titrate); under tiered pricing it is a floor (it almost certainly will). Deciding which kind of number you are looking at is most of the work of reading this market.
Updated 2026-08-10 · figures captured 2026-08-09 · how we verify
Where the term bites in the current data: the verified tirzepatide field runs $215–$597/month all-in and the semaglutide field $133–$348 (captured 2026-08-09), and nearly every dollar of those spreads is explained by the vocabulary on this glossary’s pages — memberships inside or outside headline figures, flat versus tiered ladders, prepaid terms dressed as monthly prices, evidence flags separating captures from claims. Reading this market is mostly a matter of knowing which of those words applies to the number in front of you.
Applied to the current field: NexLife↗’s $215 is a ceiling; every tiered advertised figure below it is a floor. Related figures live on the pages this term links to, and every one of them regenerates from the same dataset this definition does.
See the term in action across the price database and the methodology.